Stockreport

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 [Yahoo! Finance]

Sutro Biopharma, Inc.  (STRO) 
Last sutro biopharma, inc. earnings: 11/8 07:00 am Check Earnings Report
PDF - Luvelta in combination with bevacizumab demonstrate d encouraging preliminary antitumor activity (35% response rate) across all explored dose ranges - - Expansion a [Read more]